Market Overview

UPDATE: Piper Jaffray Upgrades AtriCure to Overweight on New Management Confidence

Related ATRC
15 Biggest Mid-Day Losers For Monday
Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital

Piper Jaffray raised its rating on AtriCure (NASDAQ: ATRC) from Neutral to Overweight and increased its price target from $6 to $10.

Piper Jaffray said, "We are upgrading ATRC shares to Overweight from Neutral (and raising our PT to $10 from $6) after meeting with the newly appointed CEO, Michael Carrel. With the CEO slot filled, we believe a level of normalcy should return to operations, allowing us to return to our original thesis. As a reminder, before the former CEO exited unexpectedly, our positive viewpoint had centered on recent FDA approval that finally put Synergy “on-label” for its intended use. While the product has been for sale in the US for the last 11 years, the potential revenue was severely constrained without the ability to market, train, hold symposia, or in any way promote the use of the ablation technology for the treatment of AF."

AtriCure closed at $6.43 on Thursday.

Latest Ratings for ATRC

Nov 2017Canaccord GenuityMaintainsBuy
Mar 2017BTIG ResearchDowngradesBuyNeutral
Aug 2016Stifel NicolausMaintainsBuy

View More Analyst Ratings for ATRC
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ATRC)

View Comments and Join the Discussion!

Partner Center